Frequently Asked Questions

Per HSC 441, a drug manufacturer subject to statutory reporting is 'any person engaged in the business of producing, preparing, propagating, compounding, converting, processing, packaging, labeling, or distributing a drug, must comply with reporting requirements (exception: the term does not include a wholesale distributor or retailer of prescription drugs or a pharmacist licensed under Subtitle J, Title 3, Occupations Code).

Wholesale acquisition cost is one of the ways prescription drugs are priced. WAC is sometimes referred to as the list price of a prescription drug and is what the drug manufacturer charges a drug wholesaler. WAC does not include any rebates, prompt pay, other discounts, or other reductions in price, nor does it reflect any health insurance coverage adjustments.

These reporting requirements do not apply to manufacturers of animal or veterinary drug products, outsourcing facilities, or producers of blood and blood components intended for transfusion.

Firms that manufacture prescription medical gases are required to report.

For 2020 reporting, manufacturers may begin submitting data on Jan. 15, 2020. Beginning in 2021, the WAC reporting deadline is Jan. 15 of each year, and manufacturers will be required to submit their data no later than Jan. 15 each year.

Manufacturers should submit the WAC price in effect on Jan. 1 of each year for all NDCs.

The WAC price should be reported per unit applicable to dosage form.

Pharmaceutical drug manufacturers should register to report once they have prescription drugs on the market being sold in or into the state of Texas. It is recommended manufacturers register immediately before or during the Annual WAC Reporting period from Jan. 1 to Jan. 15. Annual WAC Report applications are opened for all registered manufacturers immediately before the Annual WAC Reporting period. After the Annual WAC Reporting period ends, manufacturers need to email the program at PDPD@dshs.texas.gov with a request to open a current Annual WAC Report application for submission.

Pharmaceutical drug manufacturers are required to register to report with the PDPD program using the firm’s main physical address and a valid firm email address. Third-party administrators that are registering for pharmaceutical drug manufacturers cannot use a third-party administrator email, contact name, or address on the registration setup application. The contact information provided on the registration setup application is required of the pharmaceutical drug manufacturer. Registration setup applications without pharmaceutical drug manufacturer contact information will not be approved.

Manufacturers should email PDPD@dshs.texas.gov to have contact information updated in the online licensing services webpage. Only DSHS can update the main contact information for a manufacturer in the online licensing services webpage.

Pharmaceutical drug manufacturers are responsible for contacting the Prescription Drug Price Disclosure Program at pdpd@dshs.texas.gov if they are no longer selling prescription drugs in or into Texas and are no longer required to report. The program needs notification so the reporting account can be closed. Pharmaceutical drug manufacturers would then need to contact the program to reinstate the reporting account if they begin selling prescription drugs in or into Texas again.

This is managed by the Texas Department of Insurance (TDI). For changes to the Insurance Code, see Chapter 1369. Please contact TDI for more information.

This is managed by TDI. Please contact TDI for more information.

The information will be made available to the public through this website.

Price increase data is currently available on the Data Overview webpage. Price increase data is posted no later than 60 days after DSHS receives it.

All Annual WAC and Price Increase Report data is available in Excel format for download on the Data Overview webpage.

In previous years there were two different templates. There are two separate templates for the Annual WAC Report and the Price Increase Report. The templates have similar formats with minor differences. Both templates are available at the Submit Your Data webpage.

If there is a price increase above the statutory limit, data for columns I and J must be completed. Otherwise, they can be left blank. For directions on how to fill out the annual report page (step 7 in the user guide), view this document.

If there is a price increase above the statutory limit and the price increase involved R&D costs, you answer "yes" for this field. For directions on how to fill out the annual report page (step 7 in the user guide), view this document.

If there is a price increase above the statutory limit, you need to answer FDA approval in the last three years and loss of patent exclusivity in the past three years.  For directions on how to fill out the annual report page (step 7 in the user guide), view this document.

Manufacturers can either individually enter their products on the annual report page (step 7 in the user guide) or attach and upload the approved annual report template on the attachments page (step 8 in the user guide). For directions on how to fill out the annual report page, view this document.

No. Once the fee payment function is available, the system will not generate an invoice. Once the payment is collected, a receipt will be generated.

Fee payments are made through the online system. Fee payment applications will appear on the main menu of the account once the report applications are submitted and approved. Payments can be made using credit card or electronic check (ACH). Once payment is made in the system, an electronic receipt is generated and emailed. All fee payments must be made online on the payment application. Physical checks are not an acceptable form of payment.

There is a flat fee of $250 per report with an $8 transaction fee. The total fee for each report is $258.

Yes. To see an example of the Annual WAC Report template, view this document.

Price change reporting is now available. To submit a price change report, log in to the online licensing services webpage.

Yes. To see an example of the Price Increase Report template, view this document.